<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/21CFR812.html">Part 812
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 812.150  Reports.
                            </h3>
                            <p class="depth1"><em>(a)</em> Investigator reports. An investigator shall prepare and submit  the following complete, accurate, and timely reports:</p><p class="depth2"><em>(1)</em> Unanticipated adverse device effects. An investigator shall  submit to the sponsor and to the reviewing IRB a report of any  unanticipated adverse device effect occurring during an investigation as  soon as possible, but in no event later than 10 working days after the  investigator first learns of the effect.</p><p class="depth2"><em>(2)</em> Withdrawal of IRB approval. An investigator shall report to the  sponsor, within 5 working days, a withdrawal of approval by the  reviewing IRB of the investigator's part of an investigation.</p><p class="depth2"><em>(3)</em> Progress. An investigator shall submit progress reports on the  investigation to the sponsor, the monitor, and the reviewing IRB at  regular intervals, but in no event less often than yearly.</p><p class="depth2"><em>(4))</em> of any deviation from the investigational plan to protect the life  or physical well-being of a subject in an emergency. Such notice shall  be given as soon as possible, but in no event later than 5 working days  after the emergency occurred. Except in such an emergency, prior  approval by the sponsor is required for changes   in or deviations from a plan, and if these changes or deviations may  affect the scientific soundness of the plan or the rights, safety, or  welfare of human subjects, FDA and IRB in accordance with Sec.  812.35(a) also is required.</p><p class="depth2"><em>(5)</em> Informed consent. If an investigator uses a device without  obtaining informed consent, the investigator shall report such use to  the sponsor and the reviewing IRB within 5 working days after the use  occurs.</p><p class="depth2"><em>(6)</em> Final report. An investigator shall, within 3 months after  termination or completion of the investigation or the investigator's  part of the investigation, submit a final report to the sponsor and the  reviewing IRB.</p><p class="depth2"><em>(7)</em> Other. An investigator shall, upon request by a reviewing IRB or  FDA, provide accurate, complete, and current information about any  aspect of the investigation.</p><p class="depth1"><em>(b)</em> Sponsor reports. A sponsor shall prepare and submit the  following complete, accurate, and timely reports:</p><p class="depth2"><em>(1)</em> Unanticipated adverse device effects. A sponsor who conducts an  evaluation of an unanticipated adverse device effect under Sec.  812.46(b) shall report the results of such evaluation to FDA and to all  reviewing IRB's and participating investigators within 10 working days  after the sponsor first receives notice of the effect. Thereafter the  sponsor shall submit such additional reports concerning the effect as  FDA requests.</p><p class="depth2"><em>(2)</em> Withdrawal of IRB approval. A sponsor shall notify FDA and all  reviewing IRB's and participating investigators of any withdrawal of  approval of an investigation or a part of an investigation by a  reviewing IRB within 5 working days after receipt of the withdrawal of  approval.</p><p class="depth2"><em>(3)</em> Withdrawal of FDA approval. A sponsor shall notify all reviewing  IRB's and participating investigators of any withdrawal of FDA approval  of the investigation, and shall do so within 5 working days after  receipt of notice of the withdrawal of approval.</p><p class="depth2"><em>(4)</em> Current investigator list. A sponsor shall submit to FDA, at 6- month intervals, a current list of the names and addresses of all  investigators participating in the investigation. The sponsor shall  submit the first such list 6 months after FDA approval.</p><p class="depth2"><em>(5)</em> Progress reports. At regular intervals, and at least yearly, a  sponsor shall submit progress reports to all reviewing IRB's. In the  case of a significant risk device, a sponsor shall also submit progress  reports to FDA. A sponsor of a treatment IDE shall submit semi-annual  progress reports to all reviewing IRB's and FDA in accordance with Sec.  812.36(f) and annual reports in accordance with this section.</p><p class="depth2"><em>(6)</em> Recall and device disposition. A sponsor shall notify FDA and  all reviewing IRB's of any request that an investigator return, repair,  or otherwise dispose of any units of a device. Such notice shall occur  within 30 working days after the request is made and shall state why the  request was made.</p><p class="depth2"><em>(7)</em> Final report. In the case of a significant risk device, the  sponsor shall notify FDA within 30 working days of the completion or  termination of the investigation and shall submit a final report to FDA  and all reviewing the IRB's and participating investigators within 6  months after completion or termination. In the case of a device that is  not a significant risk device, the sponsor shall submit a final report  to all reviewing IRB's within 6 months after termination or completion.</p><p class="depth2"><em>(8)</em> Informed consent. A sponsor shall submit to FDA a copy of any  report by an investigator under paragraph (a)(5) of this section of use  of a device without obtaining informed consent, within 5 working days of  receipt of notice of such use.</p><p class="depth2"><em>(9)</em> Significant risk device determinations. If an IRB determines  that a device is a significant risk device, and the sponsor had proposed  that the IRB consider the device not to be a significant risk device,  the sponsor shall submit to FDA a report of the IRB's determination  within 5 working days after the sponsor first learns of the IRB's  determination.</p><p class="depth2"><em>(10)</em> Other. A sponsor shall, upon request by a reviewing IRB or FDA,  provide accurate, complete, and current information about any aspect of  the investigation.  [45 FR 3751, Jan. 18, 1980, as amended at 45 FR 58843, Sept. 5, 1980; 48  FR 15622, Apr. 12, 1983; 62 FR 48948, Sept. 18, 1997]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
